- Datum02.04.2025
- UhrzeitLäuft gerade
- Veranstalter
XTB
Stefan Salomon
Moderator
Altimmune Inc. Aktie
Verkaufen
Kaufen
Altimmune Inc. Chart
Altimmune Inc. Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-5,01 %
Intraday
-15,12 %
1 Woche
-28,65 %
1 Monat
-34,19 %
Seit Jahresbeginn
-49,28 %
1 Jahr
-23,71 %
3 Jahre
57,12 %
5 Jahre
Wikifolio
Passender Service zu Altimmune Inc.
Webinar zu Altimmune Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)4,700-11,160
- Jahrestief / Hoch ($)4,700-7,830
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Altimmune Inc.
Keine Dividenden verfügbar
Termine von Altimmune Inc.
Keine aktuellen Termine
Beschreibung
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
